4SC AG: 4SC to present results from the SENSITIZE study at the (virtual) 2021 ASCO Annual Meeting
Prof. Dr. Jessica C. Hassel, Principle Investigator of the SENSITIZE study at the University Hospital Heidelberg, German…
Prof. Dr. Jessica C. Hassel, Principle Investigator of the SENSITIZE study at the University Hospital Heidelberg, German…
4SC AG (4SC, FSE Prime Standard: VSC) today provided a business update for the three months ended 30 September 2020, as…
4SC AG (4SC, FSE Prime Standard: VSC) today announced, that the Safety Review Committee consisting of clinical and drug…
Safety, tolerability and efficacy of resminostat in combination with S-1 chemotherapy will be investigated in various do…
Daily dosage of oral, anti-mitotic Eg5 inhibitor shows good safety and tolerability. Specifically, no peripheral neuropa…
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for cancer…
. - 4SC-205 ist der weltweit einzige orale Hemmstoff des Proteins Eg5-Kinesin in klinischer Entwicklung. Eg5 spielt wic…
. - 4SC-205 is the only oral inhibitor of the Eg5 kinesin protein in clinical development worldwide. Eg5 plays a crucia…
. - US Patent granted for the manufacturing process of resminostat - Resminostat manufacturing process is thus protec…
. - Phase I confirms safety and tolerability of resminostat/docetaxel combination in the planned dose regimen in Asian…